

A NEW ANTIBIOTIC PRODUCED BY A STRAIN OF ASPERGILLUS FLAVIPES

C.G. Casinovi, G. Grandolini*, R. Mercantini, N. Oddo, R. Olivieri and A. Tonolo
Laboratori di Chimica Biologica, Istituto Superiore di Sanità, Roma, Italy.

(Received in UK 1 April 1968; accepted for publication 11 April 1968)

During the researches on thermophilic fungi our attention was drawn to a strain belonging to Aspergillus flavipes series (1) which demonstrated a strong activity against gram-positive and gram-negative bacteria.

The strain F-2091/7 of our collection was grown in submerged culture in Erlenmeyer flasks of 500 ml capacity containing 100 ml of the following nutrient medium, a modification of that reported by Stoll and coworkers (2): Sucrose g.100; $\text{Ca}(\text{NO}_3)_2$ g.1; KH_2PO_4 g. 0.250; $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ g. 0.250; KCl g. 0.125; $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ g. 0.033; $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ g. 0.027; L-asparagine g.10; L-cysteine hydrochloride g. 0.01; yeast extract g. 0.1; stock solution ($\text{MnSO}_4 \cdot 7\text{H}_2\text{O}$ g. 2; KJ g. 0.5; $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ g. 0.05; $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ g. 0.05; $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ g. 0.05; H_3BO_3 g. 0.05; H_2SO_4 ml. 1; distilled water to 1000 ml) 3 drops; distilled water to 1000 ml; pH 5; sterilization: 30 min. at 100°C.

The antibiotic production began at 24°C after 3 days culture, reaching the highest activity after 7 days. At this time the maximum concentration of the antibiotic was about 300 µg/ml (the activity was measured in agar plate using a strain of B. subtilis as test organism).

The antibiotic was extracted from the fermentation broth, acidified to pH 3,5, with the same amount of chloroform, and purified by chromatography on acid alumina (C. Erba), using $\text{CHCl}_3:\text{Et}_2\text{O}=4:1$ as eluent. Repeated crystallizations of the active fraction from benzene gave the new antibiotic (I) as optically active ($[\alpha]_D^{21} = -71.8^\circ$; c=1% in 95% ethanol) white needles, m.p. 130-131°C.

Elemental analysis gave results consistent with a crude formula $\text{C}_{12}\text{H}_{15}\text{NO}_4$, confirmed by mass spectrometry (found $M^+=237.100$). The new

* On leave from Istituto di Chimica Farmaceutica, Università di Perugia, Italy.


compound is neutral and has a characteristic u.v. spectrum (λ_{\max} 330 m μ in neutral ethanol, $\epsilon = 5,4 \cdot 10^3$). Its i.r. spectrum (KBr) shows NH and/or OH bands at 3200-3000 cm^{-1} as well as saturated (1725 cm^{-1}) and unsaturated (1650 and 1615 cm^{-1}) carbonyl. The presence of a $\text{CH}_3\text{-CH-CH}_2\text{-C=}$ group is easily inferred from its NMR spectrum*: two doublets CH_3 ($J = 6.5$), each corresponding to three protons, at 0.88 and 0.91 δ , a one-proton multiplet at 2.22 δ , a two-proton multiplet (showing the 8-peak pattern characteristic for the AB part of an ABX system) centred at 2.89 δ . A three-proton sharp singlet at 2.02 δ is attributable to a $\text{CH}_3\text{-C=}$. Another singlet at 5.60 δ is easily interpreted as due to a $\text{C}^>\text{C=CH-CO-}$, while a broad singlet at 5.25 δ (9.30 δ in CDCl_3), easily exchangeable with D_2O , is due to an imidic hydrogen. This explains the evolution of ammonia when (I) is treated with NaOH. A singlet (one-proton) appearing at 4.32 δ , which does not exchange with D_2O , will be accounted for later.

The NMR data and the successive loss of fragments of 85 and 43 m.u. in the mass spectrum are consistent with the presence in (I) of $\text{CH}_3\text{-CH-CH}_2\text{CO-}$ and $\text{CH}_3\text{-CO-}$ substituents.


Catalytic hydrogenation of (I) (PtO_2 in AcOH) gives, after absorption of three moles of hydrogen, a tetrahydrocompound (II) (white prisms from AcOEt, m.p. 189-190°) analysing for $\text{C}_{12}\text{H}_{19}\text{NO}_3$ (found $M^+ = 225.136$), which on treatment with NaOH does not give NH_3 ; its i.r. spectrum does no longer show the 1725 cm^{-1} band. (II) gives, by boiling with Ac_2O , a diacetate (III), m.p. 175° (white needles from 90% ethanol; $[\alpha]_D^{21} + 6.1^\circ$; $c = 1\%$ in 95% ethanol). Some interesting features appear in the NMR spectra of (II) and (III): both show the presence of the $\text{CH}_3\text{-CO-}$ singlet as well as the pattern of the $\text{CH}_2\text{-CH}$ $\begin{matrix} \text{CH}_3 \\ \diagup \\ \diagdown \\ \text{CH}_3 \end{matrix}$ group, referred to above, displaced to lower δ values and transformed in a more complex multiplet, thus indicating some additional coupling. Their comparison shows that acetylation is accompanied by the disappearance of an amidic proton (1H, extremely broad signal at 6-7 δ in II) and by a shift of a one-proton multiplet from 4.35 (in II) to 5.45 δ (in III); hence (III) is a N,O-diacetate.

* NMR spectra were recorded on a Varian HA-100 apparatus, solvent $\text{C}_5\text{D}_5\text{N}$, internal standard TMS; chemical shifts are given in ppm, coupling constants in cps.

NMR shows that the proton on the acetylatable function arisen by reduction of a saturated keto group in (I) couples with a proton which is, in turn, also coupled to a new 8-peak pattern (two protons) centred at about 3.2δ in (II) and at about 2.85δ in (III), lacking in (I). Remembering that (II) has an oxygen less than (I) we deduce that catalytic hydrogenation also involves the reduction of a $-\text{CO}-\text{NH}-$ to a $-\text{CH}_2-\text{NH}-$ group. All the evidence reported so far demonstrates, in our opinion, that (II) contains the sequence:



Taking into account that in (II) the $\text{CH}_3-\text{CO}-$ group is yet present, as stated above on NMR basis and as confirmed both by the easy loss of a 43 m.u. from the M^+ ion and by u.v. spectrum, which cannot be accounted for only on the basis of an unsaturated amide group, we can deduce structure (II) for the tetrahydroderivative.



Consequently, the new antibiotic must have structure (I), in which the absolute stereochemistry of the asymmetric carbon remains to be elucidated.

From the allowed formula, we can classify (I) as belonging, at least formally, to the cycloheximide family, of which several members are known(3), although this is the first time that a member of this family is found in fungi.

At the contrary of cycloheximide, this new antibiotic, as shown in Table No. 1, is active against gram-positive and gram-negative bacteria, and inactive against fungi.

T A B L E I

Tested microorganism	Minimal inhibiting concentration ($\mu\text{g} / \text{ml}$)
<u>B. subtilis</u>	25
<u>St.aureus Oxford</u>	25
<u>St.aureus</u> 108 (penicillin resistant)	25
<u>E. coli</u>	25
<u>Mycobacterium phlei</u>	>100
<u>Nocardia</u> sp.	<100
<u>Streptomyces</u> sp.	<100
<u>Saccharomyces cerevisiae</u>	>1000
<u>Candida albicans</u>	>1000
<u>Penicillium</u> sp.	>1000
<u>Claviceps cynodontis</u>	< 100

Studies on possible therapeutic applications are in program.

References.

- (1) K.B. Raper and D.I. Fennel, The genus Aspergillus,
The Williams and Wilkins Co., Baltimore (1965).
- (2) A. Stoll, A. Brack, A. Hofmann and H. Kobel, U.S.Pat. 2.809.920 (1957).
- (3) S.A. Waksman and A.H. Lechevalier, The Actinomycetes, vol.III, p.50,
The Williams and Wilkins Co., Baltimore (1962).